First Week of DXCM February 2026 Options Trading

DexCom (DXCM) option strategies: selling a $55 put (bid $0.70) would commit purchase at $55 with an effective cost basis of $54.30 versus the current price of $65.95, a strike ~17% below spot with modelled 84% chance to expire worthless and a premium return of 1.27% (7.37% annualized). Alternatively, buying at $65.95 and selling a $70 covered call (bid $3.70) yields a potential 11.75% total return if called at Feb 2026, the $70 strike is ~6% OTM with a 56% chance to expire worthless and a 5.61% premium (32.50% annualized). Implied volatility is ~49% on the put and 51% on the call versus a 12‑month trailing volatility of 45%, framing these as income/volatility plays for investors considering DXCM exposure.

Analysis

Market structure: The options data signals short-term investor preference to monetize DXCM's near-term range rather than directional bets—put $55 (17% OTM) shows an 84% chance to expire worthless and a net cash-secured yield of 1.27% to Feb 2026, while the $70 covered-call yields 11.75% with a 56% OTM survival probability. Implied volatility ~50% vs realized 45% implies sellers are receiving a ~5pt premium; that favors premium-selling strategies and suggests market participants price modestly higher event risk than history.

Risk assessment: Tail risks include FDA action, device recall, or reimbursement cuts that could drive >30-50% downside quickly in quarters; regulatory or supply chain shocks within 0–3 months would blow through the $55 put hedge. Over 3–12 months, adoption/reimbursement trends and competitive sensor launches (Abbott/Medtronic) are decisive; positive Medicare/insurer wins would compress IV and lift shares.

Trade implications: With IV richer than realized, prioritize defined-risk premium-selling (cash-secured puts or verticals) into Feb 2026 to harvest ~1–12% discrete yields depending on strike, and use covered calls to monetize positions if long. Size exposure to DXCM at tactical 1–4% portfolio per trade, increase to 3–6% only on confirmed fundamental beats or price < $60.

Contrarian angles: The consensus underweights the assignment optionality: selling naked puts at $55 implicitly values owning DXCM at $54.30—if you’d accept that business-risked entry, the market is underpricing ownership carry. Conversely, if clinical or reimbursement progress accelerates, upside is capped by covered-call use, creating mispricings to exploit by buying stock and selling calls or buying calls outright after IV compresses below 40%.

Key Decisions for Investors

• Sell 1x Feb 2026 DXCM $55 cash-secured put (collect $0.70); max capital commit $5,500 per contract, effective buy price $54.30 (17% discount). Size 1–2% portfolio; close if DXCM < $50 (loss control) or IV > 65% (re-price risk).
• If unwilling to accept assignment, sell a Feb 2026 DXCM put credit spread: sell $55 / buy $50 (defined max loss ~$4.40/share). Target net credit ≈ $0.60; risk per contract ~$440; use for 1–3% tactical allocation.
• If long DXCM shares, sell Feb 2026 $70 covered calls (collect $3.70) to lock ~11.75% to expiry; allocate to existing position sizes (cap at 3% portfolio) and roll up only if stock >$72 with IV >60%.
• Establish a small core long (2–4% portfolio) on pullback to <$60 or if IV compresses <40% (buy-the-vol-compression). Set a 20% trailing stop and plan 12–24 month hold targeting upside from adoption/reimbursement catalysts.